Figure 1.
Changes of best-corrected visual acuity from baseline to month 12 in patients with macular edema secondary to branch retinal vein occlusion treated by intravitreal aflibercept or bevacizumab.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.